William Blair Issues Pessimistic Forecast for AXSM Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at William Blair dropped their Q1 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Tuesday, February 18th. William Blair analyst M. Minter now anticipates that the company will post earnings of ($1.46) per share for the quarter, down from their prior forecast of ($0.95). William Blair has a “Outperform” rating on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.26) per share. William Blair also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.28) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($4.23) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.93 EPS, Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $2.38 EPS and FY2027 earnings at $13.85 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.

Other analysts have also recently issued reports about the company. StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Robert W. Baird raised their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Truist Financial lifted their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $153.00 target price on shares of Axsome Therapeutics in a research report on Wednesday. Finally, Leerink Partners raised their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $155.47.

Axsome Therapeutics Stock Performance

Shares of NASDAQ:AXSM opened at $129.15 on Friday. The firm’s 50 day moving average is $100.34 and its two-hundred day moving average is $94.46. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.37 and a current ratio of 2.11. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $134.18.

Insiders Place Their Bets

In other news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Axsome Therapeutics

A number of hedge funds have recently modified their holdings of AXSM. JPMorgan Chase & Co. increased its stake in Axsome Therapeutics by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock worth $19,062,000 after purchasing an additional 27,534 shares in the last quarter. Strategic Financial Concepts LLC purchased a new stake in Axsome Therapeutics during the fourth quarter valued at about $2,599,000. PDT Partners LLC acquired a new position in shares of Axsome Therapeutics in the third quarter worth about $1,052,000. Pallas Capital Advisors LLC purchased a new position in shares of Axsome Therapeutics in the fourth quarter worth approximately $2,237,000. Finally, Captrust Financial Advisors acquired a new stake in shares of Axsome Therapeutics during the third quarter valued at approximately $514,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.